Activation of MIP-2 and MCP-5 Expression in Methylmercury-Exposed Mice and Their Suppression by N-Acetyl-L-Cysteine.


Journal

Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 01 07 2019
accepted: 02 02 2020
revised: 15 01 2020
pubmed: 11 2 2020
medline: 22 12 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

Methylmercury (MeHg) is a well-known neurotoxin of the central nervous system (CNS). Neuroinflammation is one of the main pathways of MeHg-induced CNS impairment. This study aims to investigate the expressions of IL-6, MIP-2, and MCP-5, as biomarkers in relation with MeHg-induced CNS impairment and N-acetyl-L-cysteine (NAC) treatment in mice, as well as histopathological changes of brain tissue and clinical symptom such as ataxia. Twenty male Balb/c mice, aged 8-9 weeks, were divided into 4 groups and treated with saline (control), NAC [150 mg/kg body weight (BW) day], MeHg (4 mg Hg/kg BW), or a combination of MeHg and NAC for 17 days. MeHg induced the expression of IL-6, MIP-2, and MCP-5 in the serum, with median values (those in controls) of 55.06 (9.44), 15.94 (9.30), and 458.91 (239.91) mg/dl, respectively, and a statistical significance was observed only in IL-6 expression (p < 0.05). MIP-2 and MCP-5 expressions tended to increase in the cerebrum of MeHg-treated group compared with controls; however, the difference was not statistically significant. MeHg treatment also increased IL-6 expression in the cerebellum (7.73 and 4.81 mg/dl in MeHg-treated group and controls, respectively), with a marginal significance. NAC significantly suppressed MeHg-induced IL-6 and MIP-2 expressions in the serum (p < 0.05 for both), and slightly reduced MCP-5 expression in the cerebrum. Ataxia was observed in all MeHg-treated mice after 9-day exposure as well as the decrease of intact Purkinje cells in brain tissue (p < 0.05). These findings suggest that MeHg induced neurotoxicity by elevating the expression of IL-6, MIP-2, and MCP-5 and causing ataxia symptoms, and NAC reduced MeHg-mediated effects on the CNS.

Identifiants

pubmed: 32040762
doi: 10.1007/s12640-020-00174-4
pii: 10.1007/s12640-020-00174-4
doi:

Substances chimiques

Ccl12 protein, mouse 0
Chemokine CXCL2 0
Cxcl2 protein, mouse 0
Methylmercury Compounds 0
Monocyte Chemoattractant Proteins 0
Acetylcysteine WYQ7N0BPYC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

827-834

Subventions

Organisme : Universitas Diponegoro
ID : 38/UN.7.3.4/HK/2017

Références

Toxicol Appl Pharmacol. 2000 Aug 15;167(1):1-11
pubmed: 10936073
Diabetes. 2006 Jun;55(6):1614-24
pubmed: 16731823
Toxicology. 1988 Sep;51(1):47-55
pubmed: 3413800
J Toxicol Environ Health A. 2017;80(19-21):1145-1155
pubmed: 28850017
Toxicol Appl Pharmacol. 2011 Nov 1;256(3):405-17
pubmed: 21601588
J Cereb Blood Flow Metab. 2010 Mar;30(3):459-73
pubmed: 19904283
Regul Toxicol Pharmacol. 2016 Jul;78:1-7
pubmed: 27032305
Brain Res. 1994 Feb 21;637(1-2):10-4
pubmed: 8180786
Infect Immun. 1999 May;67(5):2590-601
pubmed: 10225925
J Histochem Cytochem. 2006 Apr;54(4):427-41
pubmed: 16322601
J Neuroimmunol. 2005 Jul;164(1-2):134-9
pubmed: 15885808
J Vis Exp. 2010 May 21;(39):
pubmed: 20495529
J Neuroimmunol. 2015 Jul 15;284:1-9
pubmed: 26025052
J Toxicol Sci. 2012;37(6):1279-82
pubmed: 23208444
Cell Microbiol. 2004 Jun;6(6):555-67
pubmed: 15104596
Neurosci Lett. 2007 Apr 18;416(3):217-20
pubmed: 17368937
Microbes Infect. 2006 Apr;8(4):974-83
pubmed: 16488173
Toxicol Sci. 2012 Jan;125(1):209-18
pubmed: 21976372
J Appl Toxicol. 2014 Aug;34(8):914-23
pubmed: 24243536
Brain. 2004 Jun;127(Pt 6):1437-45
pubmed: 15115715
Neurosci Lett. 2009 Sep 18;461(2):85-9
pubmed: 19539721
J Neurochem. 2009 Mar;108(6):1343-59
pubmed: 19154336
J Exp Med. 1997 Jan 6;185(1):99-109
pubmed: 8996246
J Infect Dis. 2005 Mar 1;191(5):768-75
pubmed: 15688294
Glia. 2002 Jan;37(1):43-52
pubmed: 11746782
J Vasc Surg. 2015 Mar;61(3):777-86
pubmed: 24388697
Eur J Med Res. 2017 Nov 9;22(1):45
pubmed: 29122013
J Leukoc Biol. 2010 Mar;87(3):501-8
pubmed: 20007247
J Toxicol Sci. 2012;37(6):1275-8
pubmed: 23208443
J Immunol. 2000 Oct 1;165(7):4015-23
pubmed: 11034412
Mol Pharmacol. 2002 Dec;62(6):1418-30
pubmed: 12435810
Environ Health Perspect. 2008 Jan;116(1):26-31
pubmed: 18197295
J Appl Toxicol. 2019 Feb;39(2):221-230
pubmed: 30175511
BMC Complement Altern Med. 2017 Aug 10;17(1):397
pubmed: 28797292
J Toxicol Sci. 2011 Jun;36(3):389-91
pubmed: 21628967
J Appl Toxicol. 2017 May;37(5):611-620
pubmed: 27917510
J Neuroinflammation. 2007 May 02;4:12
pubmed: 17474992
Life Sci. 2015 Aug 1;134:16-21
pubmed: 26006043
Biochim Biophys Acta. 2013 Aug;1830(8):4117-29
pubmed: 23618697

Auteurs

Muflihatul Muniroh (M)

Department of Physiology, Faculty of Medicine Diponegoro University, Tembalang Semarang, 50275, Indonesia. muflihatul.muniroh@fk.undip.ac.id.

Ainun Rahmasari Gumay (AR)

Department of Physiology, Faculty of Medicine Diponegoro University, Tembalang Semarang, 50275, Indonesia.

Darmawati Ayu Indraswari (DA)

Department of Physiology, Faculty of Medicine Diponegoro University, Tembalang Semarang, 50275, Indonesia.

Yuriz Bahtiar (Y)

Department of Physiology, Faculty of Medicine Diponegoro University, Tembalang Semarang, 50275, Indonesia.

Hardian Hardian (H)

Department of Physiology, Faculty of Medicine Diponegoro University, Tembalang Semarang, 50275, Indonesia.

Saekhol Bakri (S)

Department of Public Health, Faculty of Medicine Diponegoro University, Semarang, 50275, Indonesia.

Nani Maharani (N)

Department of Pharmacology and Therapy, Faculty of Medicine Diponegoro University, Semarang, 50275, Indonesia.

Vega Karlowee (V)

Department of Anatomical Pathology, Faculty of Medicine Diponegoro University, Semarang, 50275, Indonesia.

Chihaya Koriyama (C)

Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Health Sciences, Kagoshima, 890-8520, Japan.

Megumi Yamamoto (M)

Department of Environment and Public Health, National Institute for Minamata Disease, Kumamoto, 867-0008, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH